PTC Therapeutics Deal History & Licensing Activity
PTC Therapeutics is a biotech headquartered in US. Over the past three years, PTC Therapeutics has been involved in 3 licensing and acquisition transactions, with a primary focus on Gene Therapy (2 deals). The company currently has 6 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
6
Top Modality
Gene Therapy
Focus Area
Rare Disease
PTC Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving PTC Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| isaralgagene civaparvovec / ST-920 | Sangamo Therapeutics | Gene Therapy | Phase 1 | acquisition | Aug 12, 2026 |
| votoplam | Novartis | Other | Phase 2 | license | Feb 19, 2026 |
PTC Therapeutics Pipeline Focus
Therapeutic areas and modalities where PTC Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
PTC Therapeutics Strategic Signals
Key indicators of PTC Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
PTC Therapeutics Clinical Pipeline
PTC Therapeutics has 6 active clinical trials across 3 development phases.
1
Unknown
2
Phase 2
3
Phase 3
See How Your Asset Matches PTC Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About PTC Therapeutics Licensing & Deal Activity
PTC Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, PTC Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for PTC Therapeutics include Rare Disease (4 deals and trials), Neurology (3 deals and trials), Metabolic (2 deals and trials), and Autoimmune (1 deal and trial). In terms of modality, PTC Therapeutics has shown particular interest in gene therapy, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for PTC Therapeutics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against PTC Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.